In yesterday’s Wall Street session, Geron Corporation (NASDAQ:GERN) shares traded at $2.55, down -5.56% from the previous session.
GERN stock price is now -19.02% away from the 50-day moving average and -7.14% away from the 200-day moving average. The market capitalization of the company currently stands at $1.33B.
With the price target of $3, Goldman recently initiated with Neutral rating for Geron Corporation (NASDAQ: GERN).
In other news, LAWLIS V BRYAN, Director sold 35,000 shares of the company’s stock on May 11. The stock was sold for $105,000 at an average price of $3.00. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, Director Molineaux Susan sold 35,000 shares of the business’s stock. A total of $86,800 was realized by selling the stock at an average price of $2.48. Insiders disposed of 2,194,719 shares of company stock worth roughly $5.6 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GERN stock. A new stake in Geron Corporation shares was purchased by MARSHALL WACE, LLP during the first quarter worth $25,017,000. ARMISTICE CAPITAL, LLC invested $11,475,000 in shares of GERN during the first quarter. In the first quarter, SEGALL BRYANT & HAMILL, LLC acquired a new stake in Geron Corporation valued at approximately $8,784,000. BOXER CAPITAL, LLC acquired a new stake in GERN for approximately $7,650,000. OPALEYE MANAGEMENT INC. purchased a new stake in GERN valued at around $5,993,000 in the second quarter. In total, there are 249 active investors with 50.50% ownership of the company’s stock.
Thursday morning saw Geron Corporation (NASDAQ: GERN) opened at $2.7200. During the past 12 months, Geron Corporation has had a low of $1.95 and a high of $3.84. As of last week, the company has a debt-to-equity ratio of 0.17, a current ratio of 5.20, and a quick ratio of 5.20. The fifty day moving average price for GERN is $3.1278 and a two-hundred day moving average price translates $2.7469 for the stock.
The latest earnings results from Geron Corporation (NASDAQ: GERN) was released for Jun, 2023. The company reported revenue of $29000.0 for the quarter, compared to $73000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -60.27 percent.
Geron Corporation(GERN) Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
